A new study abstract published in United European Gastroenterology concluded that patients who switched from Celltrion’s Remsima® (CT-P13) to Samsung Bioepis’ Flixabi®/Reflexis® (SB2), both biosimilars to Janssen’s Remicade® (infliximab) was safe, did not significantly affect effectiveness or pharmacokinetics, and was not associated with major negative psychological implications.
On 26 May 2023, a study published in JAMA Network Open found in a systematic review and meta-analysis that biosimilars of adalimumab, etanercept, and infliximab were associated with clinically equivalent effects in patients with rheumatoid arthritis compared with their reference biologics.